LLY vs PFE: Stock Comparison

Eli Lilly and Company (LLY) and Pfizer, Inc. (PFE) compared side by side on 20 fundamental metrics — valuation, profitability, growth, balance sheet, and returns. Live data, updated hourly.

PFE trades at the lower earnings multiple (37.88x vs 39.6x), while LLY has the higher return on equity (92.58% vs 4.89%).

Metric LLY PFE
Stock Price $1,273.46 $30.03
Market Cap $1.20T $171.2B
P/E Ratio 39.6 37.88
P/B Ratio 31.18 1.92
P/S Ratio 13.99 2.57
EV/EBITDA 26.8 17.87
PEG Ratio 0.42 -0.63
Return on Equity 92.58% 4.89%
ROCE 41.90% 9.48%
Return on Assets 18.77% 2.16%
Gross Margin 83.40% 71.32%
Net Margin 33.53% 6.81%
Revenue Growth (1y) +44.70% -1.65%
Profit Growth (1y) +94.90% -3.12%
Debt / Equity 1.62 0.74
Current Ratio 1.35 1.27
Interest Coverage 40.43 5.92
Dividend Yield 0.58% 6.00%
Beta 0.5 0.3
1-Year Return +61.85% +30.26%

Green bold marks the higher value on each metric, or the lower value for valuation multiples and debt-to-equity. It shows direction only and is not a ranking of either stock: sector norms, one-off items and growth stage all affect how a number reads. Not investment advice.

Full LLY data →  ·  Full PFE data →  ·  Screen 4,900+ stocks →

More Comparisons

All 60 stock comparisons →